{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:11:43Z","timestamp":1794971503594,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"LEO Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s13555-020-00454-z","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T11:03:18Z","timestamp":1602586998000},"page":"1383-1396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adjunctive Use of Calcipotriene\/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-0915","authenticated-orcid":false,"given":"Jerry","family":"Bagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Hetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"issue":"9","key":"454_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199503023320907","volume":"332","author":"MW Greaves","year":"1995","unstructured":"Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332(9):581\u20138.","journal-title":"N Engl J Med"},{"key":"454_CR2","doi-asserted-by":"crossref","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64 Suppl 2:ii18\u201323 (discussion ii24\u201325).","DOI":"10.1136\/ard.2004.033217"},{"issue":"12","key":"454_CR3","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1038\/jid.2015.296","volume":"135","author":"J Takeshita","year":"2015","unstructured":"Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the us medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol. 2015;135(12):2955\u201363.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"454_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jamadermatol.2014.3456","volume":"151","author":"AW Armstrong","year":"2015","unstructured":"Armstrong AW, Bagel J, Van Voorhees AS, et al. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the medical board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151(4):432\u20138.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"454_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1365-2133.2006.07675.x","volume":"156","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007;156(2):258\u201362.","journal-title":"Br J Dermatol"},{"key":"454_CR6","doi-asserted-by":"crossref","unstructured":"Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826\u2013850.","DOI":"10.1016\/j.jaad.2008.02.039"},{"issue":"3 Pt 1","key":"454_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","volume":"41","author":"SR Rapp","year":"1999","unstructured":"Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"454_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"454_CR9","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003\u20132011. JAMA Dermatol. 2013;149(10):1180\u20135.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"454_CR10","first-page":"1209","volume":"16","author":"J Bagel","year":"2017","unstructured":"Bagel J, Gold LS. Combining topical psoriasis treatment to enhance systemic and phototherapy: a review of the literature. J Drugs Dermatol. 2017;16(12):1209\u201322.","journal-title":"J Drugs Dermatol"},{"key":"454_CR11","doi-asserted-by":"crossref","unstructured":"Korman NJ, Zhao Y, Lu J, et al. Psoriasis disease severity affects patient satisfaction with treatment. Dermatol Online J. 2015;21(7).","DOI":"10.5070\/D3217028110"},{"key":"454_CR12","doi-asserted-by":"crossref","unstructured":"Stein Gold LF. Topical therapies for psoriasis: improving management strategies and patient adherence. Semin Cutan Med Surg. 2016;35(2 Suppl 2):S36-S44 (quiz S45).","DOI":"10.12788\/j.sder.2016.006"},{"issue":"5","key":"454_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","volume":"152","author":"AY Finlay","year":"2005","unstructured":"Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"454_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaad.2020.02.077","volume":"83","author":"L Stein Gold","year":"2020","unstructured":"Stein Gold L, Hansen JB, Patel D, et al. PGAxBSA composite versus PASI: comparison across disease severities and as therapeutic response measure for Cal\/BD foam in plaque psoriasis. J Am Acad Dermatol. 2020;83(1):131\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"454_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","volume":"66","author":"A Robinson","year":"2012","unstructured":"Robinson A, Kardos M, Kimball AB. Physician global assessment (PGA) and psoriasis area and severity index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66(3):369\u201375.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"454_CR16","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"454_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-018-0279-5","volume":"9","author":"BE Strober","year":"2019","unstructured":"Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther (Heidelb). 2019;9(1):5\u201318.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"454_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/jamadermatol.2019.3717","volume":"156","author":"FM Bruins","year":"2019","unstructured":"Bruins FM, Bronckers I, Groenewoud HMM, et al. Association between quality of life and improvement in psoriasis severity and extent in pediatric patients. JAMA Dermatol. 2019;156(1):72\u20138.","journal-title":"JAMA Dermatol"},{"key":"454_CR19","doi-asserted-by":"crossref","unstructured":"Seneschal J, Lacour JP, Bewley A, et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol. 2020.","DOI":"10.1111\/jdv.16568"},{"issue":"12","key":"454_CR20","first-page":"1468","volume":"14","author":"C Leonardi","year":"2015","unstructured":"Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris\u2014a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468\u201377.","journal-title":"J Drugs Dermatol"},{"key":"454_CR21","doi-asserted-by":"crossref","unstructured":"Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643\u2013659.","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"454_CR22","unstructured":"Enstilar\u00ae (calcipotriene and betamethasone dipropionate) foam [package insert]. Madison, NJ: LEO Pharma Inc; 2019."},{"key":"454_CR23","unstructured":"Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34\u201341."},{"key":"454_CR24","doi-asserted-by":"crossref","unstructured":"Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119\u2013126.","DOI":"10.1111\/jdv.13859"},{"issue":"8","key":"454_CR25","first-page":"951","volume":"15","author":"L Stein Gold","year":"2016","unstructured":"Stein Gold L, Lebwohl M, Menter A, et al. Aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate is highly efficacious in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. J Drugs Dermatol. 2016;15(8):951\u20137.","journal-title":"J Drugs Dermatol"},{"key":"454_CR26","unstructured":"Bagel J, Zapata J, Nelson E. A prospective, open-label study evaluating adjunctive calcipotriene 0.005%\/betamethasone dipropionate 0.064% foam in psoriasis patients with inadequate response to biologic therapy. J Drugs Dermatol. 2018;17(8):845\u2013850."},{"issue":"2","key":"454_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1365-2133.2010.09791.x","volume":"163","author":"D Thaci","year":"2010","unstructured":"Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol\/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163(2):402\u201311.","journal-title":"Br J Dermatol"},{"key":"454_CR28","unstructured":"Kircik LH. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial. J Drugs Dermatol. 2011;10(8):878\u2013882."},{"issue":"6","key":"454_CR29","first-page":"327","volume":"70","author":"TS Housman","year":"2002","unstructured":"Housman TS, Mellen BG, Rapp SR, et al. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70(6):327\u201332.","journal-title":"Cutis"},{"key":"454_CR30","unstructured":"IBM Micromedex Red Book\u00ae. IBM.Com\/products\/micromedex-red-book\/pricing. Accessed 7 July 2020."},{"issue":"9","key":"454_CR31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40273-018-0667-9","volume":"36","author":"TJ Mattingly 2nd","year":"2018","unstructured":"Mattingly TJ 2nd, Levy JF, Slejko JF, et al. Estimating drug costs: how do manufacturer net prices compare with other common us price references? Pharmacoeconomics. 2018;36(9):1093\u20139.","journal-title":"Pharmacoeconomics"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-020-00454-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T09:52:47Z","timestamp":1634118767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-020-00454-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1007\/s13555-020-00454-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"25 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}